Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CCT 137690

Known as: CCT-137690, CCT137690 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines
Long non-coding RNAs (lncRNAs) are involved in a range of biological processes, such as cellular differentiation, migration… Expand
Is this relevant?
2019
2019
Abstract 298: Identification and evaluation of novel drug combinations with aurora kinase inhibitor CCT137690 for enhanced efficacy in 2D monolayer and 3D spheroid model of oral cancer cells
Background: Oral cancer is the most prevalent subtype of head and neck cancers with a high incidence among men in South-Central… Expand
Is this relevant?
2019
2019
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells
ABSTRACT Oral cancer is the most prevalent subtype of head and neck cancers and arises mainly from squamous cells of the oral… Expand
Is this relevant?
2017
2017
Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
BACKGROUND & AIMS Induction of nonapoptotic cell death could be an approach to eliminate apoptosis-resistant tumors. We… Expand
Is this relevant?
2014
2014
Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy
Colorectal cancer is the third most commonly diagnosed cancer worldwide. Although surgery remains the best treatment for this… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Abstract 3816: DNA variation at BARD1 predicts response to aurora kinase inhibition in neuroblastoma.
Background: Neuroblastoma remains responsible for a disproportionately high number of pediatric cancer deaths, necessitating… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD+ acute myeloid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora… Expand
Is this relevant?
2010
2010
Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo
Abstract 3289 The Aurora kinases are a family of serine-threonine kinases that play key roles in different stages of mitosis… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE